source
- REVELUTION-2 trial assesses cardiovascular safety of relugolix plus abiraterone in high‑risk prostate cancerThe REVELUTION-2 study is focused on measuring the heart‑related risks associated with a hormone‑therapy regimen that combines relugolix and abiraterone acetate in patients with high‑risk prostate…
- Experts highlight need for broader monitoring in polycythemia vera as patient shows disease progression despite controlled hematocritA 68-year‑old woman with a six‑year history of polycythemia vera (PV) and prior deep‑vein thrombosis has kept her hematocrit below 45% on hydroxyurea, indicating good control of that metric. Desp…